A comparative study of adduct formation between the anticancer ruthenium(III) compound HInd trans-[RuCl4(Ind)2] and serum proteins

被引:74
作者
Piccioli, F
Sabatini, S
Messori, L
Orioli, P
Hartinger, CG
Keppler, BK
机构
[1] Univ Florence, Dept Chem, I-50121 Florence, Fi, Italy
[2] Univ Vienna, Inst Inorgan Chem, A-1090 Vienna, Austria
关键词
anticancer drugs; ruthenium(III) complexes; serum albumin; serum transferrin;
D O I
10.1016/j.jinorgbio.2004.04.002
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Formation of adducts between the antitumor ruthenium(III) complex [HInd] trans-[RuCl4 (Ind)(2)] (KP1019) and the plasma proteins serum albumin and serum transferrin was investigated by UV-vis spectroscopy, for metal-to-protein ratios ranging from 1:1 to 5:1. In both cases, formation of tight metal-protein conjugates was observed. Similar spectroscopic features were observed for both albumin and transferrin derivatives implying a similar binding mode of the ruthenium species to these proteins. Surface histidines are the probable anchoring sites for the bound ruthenium(III) ions in line with previous crystallographic results. In order to assess the stability of the KP1019-protein adducts the influence of pH, reducing agents and chelators was analysed by UV-vis spectroscopy. Notably, there was no effect of addition of EDTA on the UV-vis spectra of the conjugates. The pH-stability was high in the pH range 5-8. Experiments with sodium ascorbate showed that there was just some alteration of selected bands. The implications of the present results are discussed in relation to the pharmacological behavior of this novel class of antitumor compounds. (C) 2004 Elsevier Inc. All rights reserved.
引用
收藏
页码:1135 / 1142
页数:8
相关论文
共 23 条
[1]  
[Anonymous], 1999, TOP BIOL INORG CHEM
[2]   Biological role of adduct formation of the ruthenium(III) complex NAMI-A with serum albumin and serum transferrin [J].
Bergamo, A ;
Messori, L ;
Piccioli, F ;
Cocchietto, M ;
Sava, G .
INVESTIGATIONAL NEW DRUGS, 2003, 21 (04) :401-411
[3]   Non-platinum chemotherapeutic metallopharmaceuticals [J].
Clarke, MJ ;
Zhu, FC ;
Frasca, DR .
CHEMICAL REVIEWS, 1999, 99 (09) :2511-2533
[4]   Ruthenium metallopharmaceuticals [J].
Clarke, MJ .
COORDINATION CHEMISTRY REVIEWS, 2002, 232 (1-2) :69-93
[5]   Tumour-inhibiting platinum complexes-state of the art and future perspectives [J].
Jakupec, MA ;
Galanski, M ;
Keppler, BK .
REVIEWS OF PHYSIOLOGY, BIOCHEMISTRY AND PHARMACOLOGY, VOL 146, 2003, 146 :1-53
[6]  
Keppler B. K., 1989, PROGR CLIN BIOCH MED, V10, P41, DOI 10.1007/978-3-642-74760-1_3
[7]  
Keppler B. K., 1993, METAL COMPLEXES CANC, P187
[8]  
KEPPLER BK, 1997, BIOINORGANIC CHEM TR, P123
[9]  
Kratz F, 1996, Met Based Drugs, V3, P15, DOI 10.1155/MBD.1996.15
[10]  
KRATZ F, 1994, J BIOL CHEM, V269, P2581